Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accumulated Depreciation (2019 - 2025)

Revolution Medicines has reported Accumulated Depreciation over the past 7 years, most recently at $28.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation at $28.5 million for Q4 2025, up 30.66% from a year ago — trailing twelve months through Dec 2025 was $28.5 million (up 30.66% YoY), and the annual figure for FY2025 was $28.5 million, up 30.66%.
  • Accumulated Depreciation for Q4 2025 was $28.5 million at Revolution Medicines, up from $27.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for RVMD hit a ceiling of $28.5 million in Q4 2025 and a floor of $8.7 million in Q1 2021.
  • Median Accumulated Depreciation over the past 5 years was $17.3 million (2023), compared with a mean of $17.3 million.
  • Biggest five-year swings in Accumulated Depreciation: surged 41.2% in 2021 and later rose 19.86% in 2024.
  • Revolution Medicines' Accumulated Depreciation stood at $10.8 million in 2021, then surged by 34.01% to $14.5 million in 2022, then increased by 22.12% to $17.7 million in 2023, then rose by 23.34% to $21.8 million in 2024, then skyrocketed by 30.66% to $28.5 million in 2025.
  • The last three reported values for Accumulated Depreciation were $28.5 million (Q4 2025), $27.0 million (Q3 2025), and $25.0 million (Q2 2025) per Business Quant data.